Regulation & Compliance

With its new EviChat AI, Woodway Assurance’s EviData 2.0 automates complex data privacy risk assessments, promising to unlock faster innovation.

The meal kit giant partners with the celebrity chef for an Italian-inspired menu, a strategic move to capture a larger slice of the competitive market.

With a massively oversubscribed bond offering, Canada's leading alternative lender signals its rapid ascent into the financial mainstream. Here's what it means.

Renewbrook Energy acquires PosiGen's distressed solar assets, promising stability for thousands of customers left in limbo after PosiGen's bankruptcy.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

ZEISS launches Collaborative Care, a cloud-based solution to connect optometrists and ophthalmologists, streamlining referrals and data sharing for better care.

Bitcoin miner Abits Group raises needed cash in a dilutive offering, sending its stock plunging and shining a spotlight on its controversial dealmaker.

Argentina's Entre Ríos province launches a cash offer to buy back 2028 notes, funded by a new bond, aiming to ease debt and boost investment.

Most hospitals have static defenses ill-equipped for modern threats. A new, free framework offers a clinically-informed path to a dynamic Zero Trust posture.

Amid financial headwinds, CISO Global appoints a new EVP to accelerate AI innovation, enhance operational efficiency, and gain a competitive edge.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

As cardiovascular disease affects nearly half of US adults, experts are urging a shift to existing, life-saving therapies that are widely ignored.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

A 94% surge in water damage claims reveals a growing crisis, yet a new survey shows over half of Canadians plan no action to protect their homes.